Therefore, the screening of molecular targets for the treatment of androgen-independent prostate cancer, e.g., VEGFR-3 in the present study, provides important information for elucidating the pathogenesis of prostate cancer and developing novel drugs for its treatment. This evidence concerns the gene FLT4 and prostate cancer.